Clinical Decision Support Systems (CDSS) Market Trends By Component (Software), Product (Integrated CDSS), Model (Knowledge-Based CDSS) Delivery Mode (On-Premise CDSS), Mode of Advice (Active CDSS), Setting (Inpatient Setting), Type (Therapeutic CDSS), Application (Advanced CDSS), Growth Opportunity, Size, Demand, Technology and Regional Analysis Global Forecast Till 2023.
The Clinical Decision Support Systems (CDSS) Market Size is set to witness a CAGR of 12%, which projects above-average growth for the global market.
The Clinical Decision Support Systems (CDSS) market is growing significantly over the past few years. The healthcare industry is witnessing a spurting growing due to the ever-increasing population that is prompting the need for effective treatment and care. The Players that leads the global CDSS market include
Request for a FREE [emailprotected]https://www.marketresearchfuture.com/sample_request/6038
By Latest Product launches and investment in R&D are a few of the important strategies employed by the top players in the global market to facilitate growth.
Prominent players analyzed in the report include
Allscripts
Carestream
Agfa-Gevaert Group
Elsevier B.V.
Athenahealth
Hearst Health
Cerner Corporation
Meditech
and Epic Systems Corporation
Wolters Kluwer Health
and among others.
Clinical Decision Support Systems (CDSS) Market Segmentation:
The global CDSS market is segmented into component, product, model, delivery mode, mode of advice, settings, type, application, and region. By component, the market is segmented into services, software, and hardware. Software accounted for the largest share of the market and valued USD 493.43 million in 2017 and is expected to maintain its lead while reaching an evaluation of USD 982.42 million by the end of 2023.
By product, the market is segmented into integrated CDSS and standalone CDSS. Integrated CDSS is found to have the majority share and is expected to grow at the fastest CAGR. Integration allows healthcare professionals to access solutions that are interconnected and share a common user interface and database, thus simplifying the process.
By model, the market is segmented into Knowledge-based CDSS, and Non-Knowledge-based CDSS. Knowledge-based CDSS accounts for the majority share of the market due to the high number of advantages this system has over non-knowledge based CDSS.
By delivery mode, the market is segmented into in-premise and cloud-based systems. With global technology moving toward adoption of cloud-based systems, the healthcare sector is no different. The low capital and operational costs incurred in the implementation of cloud-based systems is highly beneficial as compared to on-premise systems.
By mode of advice, the market is segmented into passive CDSS and active CDSS. The active CDSS segment accounts for the largest share of the market with approximately 75% of the total share.
By settings, the market is segmented into inpatient settings and ambulatory care settings. Inpatient settings account for over 70% of the total market due to the requirement of a large volume of patient data that is captured and analyzed by healthcare professionals.
By type, the market is segmented into therapeutic clinical decision support system and diagnostic clinical decision support system. Due to its ability to transform clinical health practices by providing a user interface with the best therapeutic practices, the therapeutic CDSS segment has the leading market position.
By application, the market is segmented into conventional clinical support systems and advanced clinical decision support system. The advanced CDSS segment accounts for the largest segment with the highest CAGR of 12.34% during the assessment period. Users of CDSS has opting to upgrade conventional systems to include premium functions such as treatment planning protocol, population health management, patient record management, protocol validation, reasoning based models and health economics management too.
Browse Complete Premium Report [emailprotected]https://www.marketresearchfuture.com/reports/clinical-decision-support-systems-market-6038
18 LIST OF TABLES
TABLE 1 PRIMARY INTERVIEWS
TABLE 2 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 20152023 (USD MILLION)
TABLE 3 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SOFTWARE, BY REGION, 20152023 (USD MILLION)
TABLE 4 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SERVICES, BY REGION, 20152023 (USD MILLION)
TABLE 5 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR HARDWARE, BY REGION, 20152023 (USD MILLION)
TABLE 6 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 20152023 (USD MILLION)
TABLE 7 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR INTEGRATED CDSS, BY REGION, 20152023 (USD MILLION)
TABLE 8 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR STANDALONE CDSS, BY REGION, 20152023 (USD MILLION)
TABLE 9 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL, 20152023 (USD MILLION)
TABLE 10 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR KNOWLEDGE-BASED CDSS, BY REGION, 20152023 (USD MILLION)
TABLE 11 GLOBAL CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR NON-KNOWLEDGE-BASED CDSS, BY REGION, 20152023 (USD MILLION)
Continued
Contact:
Market Research Future, Pune 411028
Maharashtra, India
+1 646 845 9312
Email:[emailprotected]
See the original post here:
Clinical Decision Support Systems (CDSS) Market Application Products, Applications with Biotechnology and Nature Research Report 2020 - Owned
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022